Safety and tolerability profile of the adenosine A2A receptor antagonist BIIB014 in Parkinson's disease: Pooled analysis of two placebo-controlled 8-week studies

被引：0
|
作者：
Papapetropoulos, S.
Borgohain, R.
Kellet, M.
Giladi, N.
Tomic, D.
Coppell, A.
Zhu, Y.
Barnard, J.
Miller, L.
O'Neill, G. N.
机构：
来源：
MOVEMENT DISORDERS | 2010年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
367
引用
收藏
页码：S304 / S304
页数：1
相关论文
共 50 条
  • [1] Safety and tolerability profile of the adenosine a2A receptor antagonist BIIB014 in healthy volunteers: Pooled analysis of tour phase 1 studies
    Papapetropoulos, S.
    He, P.
    Zhu, Y.
    O'Neill, G. N.
    Kwiatkowski, K.
    Donaldson, K.
    MOVEMENT DISORDERS, 2010, 25 (07) : S304 - S304
  • [2] Safety and Tolerability Profile of the Adenosine A2A Receptor Antagonist BIIB014 as an Adjunct Treatment in Parkinson's Disease (PD) Patients with Motor Fluctuations
    Papapetropoulos, Spyridon
    Borgohain, Rupam
    Kellett, Mark
    Giladi, Nir
    Tomic, Davorka
    Coppell, Alex
    Barnard, John
    Zhu, Ying
    O'Neill, Gilmore
    NEUROLOGY, 2010, 74 (09) : A318 - A318
  • [3] Pharmacokinetic profile of the adenosine A2A receptor antagonist BIIB014 in healthy volunteers
    He, P.
    Papapetropoulos, S.
    O'Neill, G. N.
    Wade, A.
    Kwiatkowski, K.
    Donaldson, K.
    MOVEMENT DISORDERS, 2010, 25 (07) : S298 - S298
  • [4] Efficacy of the Adenosine A2A Receptor Antagonist BIIB014 in Parkinson's Disease (PD) Patients with Motor Fluctuations
    Papapetropoulos, Spyridon
    Borgohain, Rupam
    Kellett, Mark
    Giladi, Nir
    Tomic, Davorka
    Coppell, Alex
    Barnard, John
    Zhu, Ying
    O'Neill, Gilmore
    NEUROLOGY, 2010, 74 (09) : A318 - A318
  • [5] The adenosine A2A receptor antagonist BIIB014 is effective in improving ON-time in Parkinson's disease (PD) patients with motor fluctuations
    Papapetropoulos, S.
    Borgohain, R.
    Kellet, M.
    Giladi, N.
    Tomic, D.
    Coppell, A.
    Barnard, J.
    Zhu, Y.
    O'Neill, G. N.
    MOVEMENT DISORDERS, 2010, 25 (07) : S305 - S305
  • [6] Impact of baseline dyskinesia on the safety and efficacy of istradefylline, an adenosine A2A receptor antagonist, in patients with Parkinson's disease: a pooled analysis of 8 clinical studies
    Isaacson, S. H.
    Hattori, N.
    Truong, D.
    Rascol, O.
    Mori, A.
    Toyama, K.
    Parno, J.
    Salzman, P. M.
    Stocchi, F.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 892 - 893
  • [7] Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunct to Levodopa in Parkinson's Disease (PD): A Pooled Safety Analysis of 4 Randomized Controlled Trials
    Pahwa, Rajesh
    Toyama, Keizo
    Parno, Jeff
    Braccia, Deborah
    Cross, Brittany
    Mori, Akihisa
    ANNALS OF NEUROLOGY, 2020, 88 : S182 - S183
  • [8] A pooled analysis for 8 randomized controlled trials of istradefylline, an adenosine A2A receptor antagonist: efficacy as adjunct to levodopa in Parkinson's disease (PD)
    Isaacson, S. H.
    Hattori, N.
    Onofrj, M.
    Mori, A.
    Toyama, K.
    Salzman, P. M.
    Ohta, E.
    LeWitt, P.
    MOVEMENT DISORDERS, 2019, 34 : S10 - S10
  • [9] A double-blind crossover, placebo-controlled study of the adenosine A2A antagonist theophylline in Parkinson's disease
    Kulisevsky, J
    Barbanoj, M
    Gironell, A
    Antonijoan, R
    Casas, T
    Pascual-Sedano, B
    CLINICAL NEUROPHARMACOLOGY, 2002, 25 (01) : 25 - 31
  • [10] EFFECT OF BASELINE DYSKINESIA ON SAFETY AND EFFICACY OF ISTRADEFYLLINE, AN A2A RECEPTOR ANTAGONIST, IN PARKINSON'S DISEASE: 8-STUDY POOLED ANALYSIS
    Truong, D.
    Hattori, N.
    Isaacson, S. H.
    Rascol, O.
    Mori, A.
    Toyama, K.
    Parno, J.
    Salzman, P. M.
    Ristuccia, R.
    Stocchi, F.
    PARKINSONISM & RELATED DISORDERS, 2020, 79 : E55 - E56
12345